TAK 285 (CAS 871026-44-7)
QUICK LINKS
TAK 285 is a synthetic molecule primarily utilized as a selective inhibitor of human epidermal growth factor receptors, HER2 and EGFR kinases. In research, TAK 285 is applied to study the signaling pathways mediated by these receptors, which are known to play a significant role in the regulation of cell growth and proliferation. Due to its selectivity, TAK 285 helps researchers to dissect the molecular mechanisms underlying the function of HER2 and EGFR, particularly in the context of cancer biology where these receptors are often overexpressed. The compound is also used to investigate the potential for targeted inhibition of kinase activity as a strategy for modulating cellular responses. Furthermore, TAK 285 is valuable for elucidating resistance mechanisms that can develop against kinase inhibitors, providing insights into how cancer cells evade chemical interventions.
TAK 285 (CAS 871026-44-7) References
- Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. | Aertgeerts, K., et al. 2011. J Biol Chem. 286: 18756-65. PMID: 21454582
- Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. | Ishikawa, T., et al. 2011. J Med Chem. 54: 8030-50. PMID: 22003817
- Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy. | Kawakita, Y., et al. 2012. Bioorg Med Chem. 20: 6171-80. PMID: 22980219
- Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model. | Nakayama, A., et al. 2013. J Cancer. 4: 557-65. PMID: 23983820
- Template-based de novo design for type II kinase inhibitors and its extented application to acetylcholinesterase inhibitors. | Su, BH., et al. 2013. Molecules. 18: 13487-509. PMID: 24184819
- Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors. | Sogabe, S., et al. 2013. ACS Med Chem Lett. 4: 201-5. PMID: 24900643
- HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285. | Takagi, S., et al. 2014. Oncoscience. 1: 196-204. PMID: 25594012
- Predicting response to HER2 kinase inhibition. | Settleman, J. 2015. Oncotarget. 6: 588-9. PMID: 25655645
- Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer. | Meng, X., et al. 2016. Amino Acids. 48: 487-97. PMID: 26439378
- Short communication for targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches- part 2. | Rampogu, S., et al. 2020. Comput Biol Chem. 87: 107242. PMID: 32417599
- Molecular recognition of tak-285 and lapatinib by inactive, active, and middle active-inactive HER2. | Martiniano, B. 2021. J Mol Model. 27: 105. PMID: 33686576
- Identification of HER2 inhibitors from curcumin derivatives using combination of in silico screening and molecular dynamics simulation. | Saibu, OA., et al. 2023. J Biomol Struct Dyn. 1-10. PMID: 36752338
- Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines. | Son, S., et al. 2023. J Enzyme Inhib Med Chem. 38: 2202358. PMID: 37096560
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TAK 285, 5 mg | sc-364627 | 5 mg | $405.00 | |||
TAK 285, 10 mg | sc-364627A | 10 mg | $700.00 |